|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Hundahl SA, Phillips JL and Menck HR: The
National Cancer Data Base Report on poor survival of US gastric
carcinoma patients treated with gastrectomy: Fifth Edition American
Joint Committee on Cancer staging, proximal disease and the
‘different disease’ hypothesis. Cancer. 88:921–932. 2000.
|
|
4
|
Karpeh MS, Leon L, Klimstra D and Brennan
MF: Lymph node staging in gastric cancer: Is location more
important than number? An analysis of 1,038 patients. Ann Surg.
232:362–371. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim L, Michael M, Mann GB and Leong T:
Adjuvant therapy in gastric cancer. J Clin Oncol. 23:6220–6232.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Green PH, Fleischauer AT, Bhagat G, Goyal
R, Jabri B and Neugut AI: Risk of malignancy in patients with
celiac disease. Am J Med. 115:191–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murakami R, Tsukuma H, Ubukata T,
Nakanishi K, Fujimoto I, Kawashima T, Yamazaki H and Oshima A:
Estimation of validity of mass screening program for gastric cancer
in Osaka, Japan. Cancer. 65:1255–1260. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Macdonald JS, Smalley SR, Bendedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar
|
|
9
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S and
Chua YJ: MAGIC Trial Participants: Perioperative chemotherapy
versus surgery alone for resectable gastroesophageal cancer. N Engl
J Med. 355:11–20. 2006. View Article : Google Scholar
|
|
10
|
Petricoin EF and Liotta LA:
SELDI-TOF-based serum proteomic pattern diagnostics for early
detection of cancer. Curr Opin Biotechnol. 15:24–30. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engwegen JY, Mehra N, Haanen JB, Bonfrer
JM, Schellens JH, Voest EE and Beijnen JH: Validation of SELDI-TOF
MS serum protein profiles for renal cell carcinoma in new
populations. Lab Invest. 87:161–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
13
|
Engwegen JY, Gast MC, Schellens JH and
Beijnen JH: Clinical proteomics: searching for better tumour
markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci.
27:251–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Engwegen JY, Helgason HH, Cats A, Harris
N, Bonfrer JM, Schellens JH and Beijnen JH: Identification of serum
proteins discriminating colorectal cancer patients and healthy
controls using surface-enhanced laser desorption ionisation-time of
flight mass spectrometry. World J Gastroenterol. 12:1536–1544.
2006.
|
|
15
|
Meuleman W, Engwegen JY, Gast MC, Beijnen
JH, Reinders MJ and Wessels LF: Comparison of normalisation methods
for surface-enhanced laser desorption and ionisation (SELDI)
time-of-flight (TOF) mass spectrometry data. BMC Bioinformatics.
9:882008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeffries N: Algorithms for alignment of
mass spectrometry proteomic data. Bioinformatics. 21:3066–3073.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guyon I, Weston J and Barnhill S: Gene
selection for cancer classification using support vector machines.
Machine Learning. 46:389–422. 2002. View Article : Google Scholar
|
|
18
|
Maciel CM, Junqueira M, Paschoal ME,
Kawamura MT, Duarte RL, Carvalho Mda G and Domont GB: Differential
proteomic serum pattern of low molecular weight proteins expressed
by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 5:31–38.
2005.PubMed/NCBI
|
|
19
|
Kosuge M, Ebina T, Ishikawa T, Hibi K,
Tsukahara K, Okuda J, Iwahashi N, Ozaki H, Yano H, Kusama I, Nakati
T, Umemura S and Kimura K: Serum amyloid A is a better predictor of
clinical outcomes than C-reactive protein in non-ST-segment
elevation acute coronary syndromes. Circ J. 71:186–190. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Timms JF, Arslan-Low E, Gentry-Maharaj A,
Luo Z, T’Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs
I and Menon U: Preanalytic influence of sample handling on
SELDI-TOF serum protein profiles. Clin Chem. 53:645–656. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Villanueva J, Martorella AJ, Lawlor K,
Philip J, Fleisher M, Robbins RJ and Tempst P: Serum peptidome
patterns that distinguish metastatic thyroid carcinoma from
cancer-free controls are unbiased by gender and age. Mol Cell
Proteomics. 5:1840–1852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Winden AW, Gast MC, Beijnen JH,
Rutgers EJ, Grobbee DE, Peeters PH and van Gils CH: Validation of
previously identified serum biomarkers for breast cancer with
SELDI-TOF MS: a case control study. BMC Med Genomics.
2:42009.PubMed/NCBI
|
|
24
|
Li J, Orlandi R, White CN, Rosenzweig J,
Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE,
Fung ET and Chan DW: Independent validation of candidate breast
cancer serum biomarkers identified by mass spectrometry. Clin Chem.
51:2229–2235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gast MC, Schellens JH and Beijnen JH:
Clinical proteomics in breast cancer: a review. Breast Cancer Res
Treat. 116:17–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
